Kingston, RI – According to filings with the U.S. Securities and Exchange Commission, MindImmune Therapeutics is raising $8,880,000.00 in new funding. Sources indicate as part of senior management President, Stevin Zorn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MindImmune Therapeutics
MindImmune Therapeutics, Inc. is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimers and Huntingtons disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated. Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.

To learn more about MindImmune Therapeutics, visit http://mindimmune.com/

Contact:
Stevin Zorn, President
401-225-4612
https://www.linkedin.com/in/stevinzorn/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved